Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis

Risk factors and treatment outcomes under program conditions for isoniazid (INH)-monoresistant tuberculosis have not been well described. Medical charts were retrospectively reviewed for all cases of culture-confirmed, INH-monoresistant tuberculosis ( n = 137) reported to the San Francisco Departmen...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical infectious diseases Vol. 48; no. 2; p. 179
Main Authors:	Cattamanchi, Adithya, Dantes, Raymund B, Metcalfe, John Z, Jarlsberg, Leah G, Grinsdale, Jennifer, Kawamura, L Masae, Osmond, Dennis, Hopewell, Philip C, Nahid, Payam
Format:	Journal Article
Language:	English
Published:	United States 15.01.2009
Subjects:	Antitubercular Agents - pharmacology Antitubercular Agents - therapeutic use Drug Resistance, Bacterial Female Humans Isoniazid - pharmacology Male Middle Aged Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - isolation & purification Pyrazinamide - adverse effects Pyrazinamide - therapeutic use San Francisco Treatment Outcome Tuberculosis - drug therapy Tuberculosis - microbiology Tuberculosis - physiopathology San Francisco
ISSN:	1537-6591, 1537-6591
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Risk factors and treatment outcomes under program conditions for isoniazid (INH)-monoresistant tuberculosis have not been well described. Medical charts were retrospectively reviewed for all cases of culture-confirmed, INH-monoresistant tuberculosis ( n = 137) reported to the San Francisco Department of Public Health Tuberculosis Control Section from October 1992 through October 2005, and those cases were compared with a time-matched sample of drug-susceptible tuberculosis cases (n = 274) In multivariate analysis, only a history of treatment for latent tuberculosis (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.5-6.4; P = .003) or for active tuberculosis (OR, 2.7; 95% CI, 1.4-5.0; P = .002) were significantly associated with INH-monoresistant tuberculosis. Of the 119 patients who completed treatment, 49 (41%) completed a 6-month treatment regimen. Treatment was extended to 7-12 months for 53 (45%) of the patients and to >12 months for 17 (14%). Treatment was most commonly extended because pyrazinamide was not given for the recommended 6-month duration (35 patients [29%]). Despite variation in treatment regimens, the combined end point of treatment failure or relapse was uncommon among patients with INH-monoresistant tuberculosis and was not significantly different for patients with drug-susceptible tuberculosis (1.7% vs. 2.2%; P = .73). A history of treatment for latent or active tuberculosis was associated with subsequent INH monoresistance. Treatment outcomes for patients with INH-monoresistant tuberculosis were excellent and were no different from those for patients with drug-susceptible tuberculosis. However, new, short-course regimens are needed because a small proportion of patients completed the 6-month treatment regimen recommended by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America, primarily because of pyrazinamide intolerance.
AbstractList	Risk factors and treatment outcomes under program conditions for isoniazid (INH)-monoresistant tuberculosis have not been well described. Medical charts were retrospectively reviewed for all cases of culture-confirmed, INH-monoresistant tuberculosis ( n = 137) reported to the San Francisco Department of Public Health Tuberculosis Control Section from October 1992 through October 2005, and those cases were compared with a time-matched sample of drug-susceptible tuberculosis cases (n = 274) In multivariate analysis, only a history of treatment for latent tuberculosis (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.5-6.4; P = .003) or for active tuberculosis (OR, 2.7; 95% CI, 1.4-5.0; P = .002) were significantly associated with INH-monoresistant tuberculosis. Of the 119 patients who completed treatment, 49 (41%) completed a 6-month treatment regimen. Treatment was extended to 7-12 months for 53 (45%) of the patients and to >12 months for 17 (14%). Treatment was most commonly extended because pyrazinamide was not given for the recommended 6-month duration (35 patients [29%]). Despite variation in treatment regimens, the combined end point of treatment failure or relapse was uncommon among patients with INH-monoresistant tuberculosis and was not significantly different for patients with drug-susceptible tuberculosis (1.7% vs. 2.2%; P = .73). A history of treatment for latent or active tuberculosis was associated with subsequent INH monoresistance. Treatment outcomes for patients with INH-monoresistant tuberculosis were excellent and were no different from those for patients with drug-susceptible tuberculosis. However, new, short-course regimens are needed because a small proportion of patients completed the 6-month treatment regimen recommended by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America, primarily because of pyrazinamide intolerance. Risk factors and treatment outcomes under program conditions for isoniazid (INH)-monoresistant tuberculosis have not been well described.BACKGROUNDRisk factors and treatment outcomes under program conditions for isoniazid (INH)-monoresistant tuberculosis have not been well described.Medical charts were retrospectively reviewed for all cases of culture-confirmed, INH-monoresistant tuberculosis ( n = 137) reported to the San Francisco Department of Public Health Tuberculosis Control Section from October 1992 through October 2005, and those cases were compared with a time-matched sample of drug-susceptible tuberculosis cases (n = 274)METHODSMedical charts were retrospectively reviewed for all cases of culture-confirmed, INH-monoresistant tuberculosis ( n = 137) reported to the San Francisco Department of Public Health Tuberculosis Control Section from October 1992 through October 2005, and those cases were compared with a time-matched sample of drug-susceptible tuberculosis cases (n = 274)In multivariate analysis, only a history of treatment for latent tuberculosis (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.5-6.4; P = .003) or for active tuberculosis (OR, 2.7; 95% CI, 1.4-5.0; P = .002) were significantly associated with INH-monoresistant tuberculosis. Of the 119 patients who completed treatment, 49 (41%) completed a 6-month treatment regimen. Treatment was extended to 7-12 months for 53 (45%) of the patients and to >12 months for 17 (14%). Treatment was most commonly extended because pyrazinamide was not given for the recommended 6-month duration (35 patients [29%]). Despite variation in treatment regimens, the combined end point of treatment failure or relapse was uncommon among patients with INH-monoresistant tuberculosis and was not significantly different for patients with drug-susceptible tuberculosis (1.7% vs. 2.2%; P = .73).RESULTSIn multivariate analysis, only a history of treatment for latent tuberculosis (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.5-6.4; P = .003) or for active tuberculosis (OR, 2.7; 95% CI, 1.4-5.0; P = .002) were significantly associated with INH-monoresistant tuberculosis. Of the 119 patients who completed treatment, 49 (41%) completed a 6-month treatment regimen. Treatment was extended to 7-12 months for 53 (45%) of the patients and to >12 months for 17 (14%). Treatment was most commonly extended because pyrazinamide was not given for the recommended 6-month duration (35 patients [29%]). Despite variation in treatment regimens, the combined end point of treatment failure or relapse was uncommon among patients with INH-monoresistant tuberculosis and was not significantly different for patients with drug-susceptible tuberculosis (1.7% vs. 2.2%; P = .73).A history of treatment for latent or active tuberculosis was associated with subsequent INH monoresistance. Treatment outcomes for patients with INH-monoresistant tuberculosis were excellent and were no different from those for patients with drug-susceptible tuberculosis. However, new, short-course regimens are needed because a small proportion of patients completed the 6-month treatment regimen recommended by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America, primarily because of pyrazinamide intolerance.CONCLUSIONSA history of treatment for latent or active tuberculosis was associated with subsequent INH monoresistance. Treatment outcomes for patients with INH-monoresistant tuberculosis were excellent and were no different from those for patients with drug-susceptible tuberculosis. However, new, short-course regimens are needed because a small proportion of patients completed the 6-month treatment regimen recommended by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America, primarily because of pyrazinamide intolerance.
Author	Osmond, Dennis Metcalfe, John Z Grinsdale, Jennifer Jarlsberg, Leah G Nahid, Payam Hopewell, Philip C Kawamura, L Masae Cattamanchi, Adithya Dantes, Raymund B
Author_xml	– sequence: 1 givenname: Adithya surname: Cattamanchi fullname: Cattamanchi, Adithya email: acattamanchi@medsfgh.ucsf.edu organization: Division of Pulmonary and Critical Care Medicine, University of California-San Francisco, San Francisco GeneralHospital, 1001 Potrero Ave., San Francisco, CA 94110, USA. acattamanchi@medsfgh.ucsf.edu – sequence: 2 givenname: Raymund B surname: Dantes fullname: Dantes, Raymund B – sequence: 3 givenname: John Z surname: Metcalfe fullname: Metcalfe, John Z – sequence: 4 givenname: Leah G surname: Jarlsberg fullname: Jarlsberg, Leah G – sequence: 5 givenname: Jennifer surname: Grinsdale fullname: Grinsdale, Jennifer – sequence: 6 givenname: L Masae surname: Kawamura fullname: Kawamura, L Masae – sequence: 7 givenname: Dennis surname: Osmond fullname: Osmond, Dennis – sequence: 8 givenname: Philip C surname: Hopewell fullname: Hopewell, Philip C – sequence: 9 givenname: Payam surname: Nahid fullname: Nahid, Payam
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/19086909$$D View this record in MEDLINE/PubMed
BookMark	eNpNkEtLxDAUhYOMOA_1J0hW7qpJ0yTNUgZfMOBG1yWPWybSJmOSIvrrLTiCi8M9HM53F2eNFiEGQOiSkhtKWnHLFRetOkErypmsBFd08c8v0Trnd0IobQk_Q0uqZkYRtUKwHXzwVg_Y7nXStkDyuXibsQ4OlwS6jBAKjlOxcYSMY48Puvg5y_jTlz32OQavv72rxhhigjzzeibKZCDZaYhzcI5Oez1kuDjeDXp7uH_dPlW7l8fn7d2usk3LSiVE0xBKHHe2cYrVhEowrNfGmdpawhvLlXTcKskNaOb62lgpNRjRK9EwVm_Q9e_fQ4ofE-TSjT5bGAYdIE65E0JKNWsuXh2LkxnBdYfkR52-ur9h6h_7Vmhe
CitedBy_id	crossref_primary_10_1183_09059180_00005314 crossref_primary_10_1093_jacamr_dlae187 crossref_primary_10_26693_jmbs03_02_161 crossref_primary_10_1007_s00586_012_2536_0 crossref_primary_10_17795_iji_34903 crossref_primary_10_1371_journal_pone_0134597 crossref_primary_10_1128_JCM_03395_13 crossref_primary_10_1016_j_rmr_2011_07_011 crossref_primary_10_4137_CMT_S6560 crossref_primary_10_1016_j_ijtb_2019_09_004 crossref_primary_10_1016_j_diagmicrobio_2017_06_018 crossref_primary_10_1371_journal_pone_0152933 crossref_primary_10_1016_j_meegid_2016_09_004 crossref_primary_10_1128_AAC_01377_15 crossref_primary_10_1371_journal_pone_0229691 crossref_primary_10_1016_j_cmi_2014_08_008 crossref_primary_10_1093_bmb_ldu011 crossref_primary_10_1302_0301_620X_96B10_34048 crossref_primary_10_1371_journal_pone_0031563 crossref_primary_10_1371_journal_pone_0286194 crossref_primary_10_3390_medicina58091280 crossref_primary_10_1016_j_meegid_2015_05_022 crossref_primary_10_1128_JCM_02639_13 crossref_primary_10_1111_j_1440_1843_2010_01738_x crossref_primary_10_1128_AAC_01474_09 crossref_primary_10_1371_journal_pone_0168955 crossref_primary_10_1513_AnnalsATS_202312_1076OC crossref_primary_10_1371_journal_pone_0086316 crossref_primary_10_3201_eid1703_101715 crossref_primary_10_1093_cid_cir406 crossref_primary_10_1186_s12889_020_09360_7 crossref_primary_10_1371_journal_pone_0196322 crossref_primary_10_1128_JCM_01196_16 crossref_primary_10_1038_ng_815 crossref_primary_10_1093_qjmed_hcu139 crossref_primary_10_1016_j_tube_2018_02_009 crossref_primary_10_1128_AAC_01655_10 crossref_primary_10_1038_ng_811 crossref_primary_10_1016_j_ijtb_2019_04_001 crossref_primary_10_1111_apm_12947 crossref_primary_10_1186_s12879_019_4333_4 crossref_primary_10_1016_S1473_3099_18_30222_6 crossref_primary_10_1136_bmjopen_2019_031663 crossref_primary_10_5588_pha_25_0002 crossref_primary_10_1186_s12889_019_7524_4 crossref_primary_10_1371_journal_pone_0037956 crossref_primary_10_1007_s11033_024_10014_9 crossref_primary_10_1513_AnnalsATS_201711_885ED crossref_primary_10_1016_S2213_2600_18_30078_X crossref_primary_10_1183_09031936_00079310 crossref_primary_10_3201_eid1807_120261 crossref_primary_10_1007_s10096_011_1167_4 crossref_primary_10_1371_journal_pone_0084197 crossref_primary_10_1038_ng_3767 crossref_primary_10_1371_journal_pmed_1001880 crossref_primary_10_1016_j_jinf_2012_01_013 crossref_primary_10_1186_s12879_017_2706_0 crossref_primary_10_1186_s12879_019_4384_6 crossref_primary_10_1093_cid_cix686 crossref_primary_10_1371_journal_pone_0137791 crossref_primary_10_3389_fmed_2023_1085010 crossref_primary_10_1016_j_ebiom_2016_06_016 crossref_primary_10_1155_2015_261925 crossref_primary_10_1513_AnnalsATS_201702_147OC crossref_primary_10_7759_cureus_42166 crossref_primary_10_1016_j_jinf_2010_03_017 crossref_primary_10_1016_j_coph_2011_07_001 crossref_primary_10_1590_0037_8682_0047_2013 crossref_primary_10_4103_amit_amit_91_23 crossref_primary_10_1172_JCI173156
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1086/595689
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1537-6591
ExternalDocumentID	19086909
Genre	Journal Article Comparative Study Research Support, N.I.H., Extramural
GeographicLocations	San Francisco
GeographicLocations_xml	– name: San Francisco
GrantInformation_xml	– fundername: NHLBI NIH HHS grantid: K23 HL 092629 – fundername: NIAID NIH HHS grantid: AI 034238 – fundername: NHLBI NIH HHS grantid: K23 HL092629 – fundername: NHLBI NIH HHS grantid: K23 HL094141 – fundername: NIAID NIH HHS grantid: R01 AI034238
GroupedDBID	--- ..I .2P .I3 .ZR 08P 0R~ 1TH 29B 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 AABZA AACGO AACZT AAJKP AAJQQ AAMVS AANCE AAOGV AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABLJU ABNGD ABNHQ ABOCM ABPLY ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ACGFO ACGFS ACHIC ACPRK ACUFI ACUKT ACUTJ ACUTO ACYHN ADBBV ADGZP ADHKW ADHZD ADIPN ADNBA ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AGINJ AGORE AGQPQ AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQKUS AQVQM ASPBG ATGXG AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C1A C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DCCCD DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HTVGU HVGLF HW0 HZ~ IOX IPSME J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KSI KSN L7B MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NPM NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ~91 ~S- 7X8
ID	FETCH-LOGICAL-c483t-6644010d5dc4d932017eb3fabdb2cc054c597d5c975bea3df2bc77aeb6f964332
IEDL.DBID	7X8
ISICitedReferencesCount	93
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000262088400008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1537-6591
IngestDate	Sat Sep 27 20:59:12 EDT 2025 Mon Jul 21 06:05:59 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	2
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c483t-6644010d5dc4d932017eb3fabdb2cc054c597d5c975bea3df2bc77aeb6f964332
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
OpenAccessLink	https://academic.oup.com/cid/article-pdf/48/2/179/864723/48-2-179.pdf
PMID	19086909
PQID	66779677
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_66779677 pubmed_primary_19086909
PublicationCentury	2000
PublicationDate	2009-01-15
PublicationDateYYYYMMDD	2009-01-15
PublicationDate_xml	– month: 01 year: 2009 text: 2009-01-15 day: 15
PublicationDecade	2000
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Clinical infectious diseases
PublicationTitleAlternate	Clin Infect Dis
PublicationYear	2009
SSID	ssj0011805
Score	2.286121
Snippet	Risk factors and treatment outcomes under program conditions for isoniazid (INH)-monoresistant tuberculosis have not been well described. Medical charts were... Risk factors and treatment outcomes under program conditions for isoniazid (INH)-monoresistant tuberculosis have not been well described.BACKGROUNDRisk factors...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	179
SubjectTerms	Antitubercular Agents - pharmacology Antitubercular Agents - therapeutic use Drug Resistance, Bacterial Female Humans Isoniazid - pharmacology Male Middle Aged Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - isolation & purification Pyrazinamide - adverse effects Pyrazinamide - therapeutic use San Francisco Treatment Outcome Tuberculosis - drug therapy Tuberculosis - microbiology Tuberculosis - physiopathology
Title	Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis
URI	https://www.ncbi.nlm.nih.gov/pubmed/19086909 https://www.proquest.com/docview/66779677
Volume	48
WOSCitedRecordID	wos000262088400008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6rK-LF92N95uA1sE0fSUEQERcP7rIHlb2VZJLCgrTrtvXgr3fSh4-LHjy0h0JISWaSb_JN5iPkMgWF-zoMmeJBxIJIxkyBHDJhEV4otAJdZ_k-P4jJRM5m8bRHrrq7MC6tslsT64Xa5ODOyJ1qn4jxuV68MqcZ5bjVVkBjhfR9BDLOpsXsi0PwZJ3AiC4tWBTG3jdlodBdkvsFVNaby2jrf7-1TTZbUElvGivYIT2b7ZL1cUub7xHbVv98ofCzPjNVmaGfueY0r0rs1RY0T2lbcLWg7qSWupyjuXqfG4Zd5hiiO9iJLcpK2yVULzl-2CdPo7vH23vW6iswCKRfsgixEIZjJjQQGMRx6JwYWqdKG80BEMsBRhsmhFiE2irfpFyDEMrqKHVVvHx-QFazPLNHhHIQVjoxXQ468BSXNohS7kEsQ8kDEw3IRTd8CdqvIyVUZvOqSLoBHJDDZgaSRVNmI0Go4uSy4uM_256QjYbk8ZgXnpJ-ip5rz8gavJXzYnlemwW-J9PxB-dfxXs
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+characteristics+and+treatment+outcomes+of+patients+with+isoniazid-monoresistant+tuberculosis&rft.jtitle=Clinical+infectious+diseases&rft.au=Cattamanchi%2C+Adithya&rft.au=Dantes%2C+Raymund+B&rft.au=Metcalfe%2C+John+Z&rft.au=Jarlsberg%2C+Leah+G&rft.date=2009-01-15&rft.eissn=1537-6591&rft.volume=48&rft.issue=2&rft.spage=179&rft_id=info:doi/10.1086%2F595689&rft_id=info%3Apmid%2F19086909&rft_id=info%3Apmid%2F19086909&rft.externalDocID=19086909
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6591&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6591&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6591&client=summon